Clinical Trial

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-02; most recent amendment 2026-01-13.
Status change: Not Yet Recruiting → Recruiting 2024-09-09
Trial Details
NCT Number NCT06353997
Lead Sponsor Providence Health & Services
Collaborators: Inhibrx Biosciences, Inc
Conditions Triple Negative Breast Cancer
Enrollment 12 participants
Start Date 2024-09-05
Primary Completion 2027-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-15